Edwards Lifesciences (EW) PT Raised to $215 at Canaccord Genuity Following PARTNER 3 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences (EW) PT Raised to $197 at Morgan Stanley
March 18, 2019 7:27 AM EDTMorgan Stanley analyst David Lewis raised the price target on Edwards Lifesciences (NYSE: EW) to $197.00 (from $180.00) while maintaining a Overweight rating.
... MoreEdwards Lifesciences (EW) PT Raised to $210 at Raymond James
March 18, 2019 7:21 AM EDTRaymond James analyst Jayson Bedford raised the price target on Edwards Lifesciences (NYSE: EW) to $210.00 (from $186.00) while maintaining a Outperform rating following the better-than-expected PARTNER 3 data.
... MoreEdwards Lifesciences (EW) PT Raised to $215 at BofA/Merrill Lynch
March 18, 2019 7:10 AM EDTBofA/Merrill Lynch analyst Bob Hopkins raised the price target on Edwards Lifesciences (NYSE: EW) to $215.00 (from $190.00) while maintaining a Buy rating.
... MoreEdwards Lifesciences (EW) PT Increased To $210 At Cowen After Strong Partner 3 Results
March 18, 2019 6:29 AM EDTCowen analyst, Joshua Jennings, reiterated his Outperform rating on shares of Edwards Lifesciences (NYSE: EW) and raised his price target to $210.00 (from $190.00) after the unveiling of the Partner 3 results at ACC19.
The analyst stated "we have increased conviction that there's... More
Edwards Lifesciences (EW) SAPIEN 3 Valve Proves Superior To Surgery in Latest Trial
March 18, 2019 6:14 AM EDTEdwards Lifesciences Corporation (NYSE: EW) announced that the results of the randomized PARTNER 3 Trial demonstrated superiority for the SAPIEN 3 transcatheter aortic valve over outcomes with surgery.
The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New... More
